Screening before synthesizing
Finding a new drug traditionally means identifying a molecule that will bind to a specific biological target, like a protein involved in a disease, without causing harmful side effects elsewhere in the body. The space of possible drug-like molecules is enormous, and physically synthesizing and testing each candidate in a lab is slow and costly. AI is increasingly used to narrow this search computationally before any physical synthesis happens: models can screen large virtual libraries of existing molecules, or even generate new candidate molecular structures, and rank them by predicted properties like how strongly they might bind a target or how likely they are to be safe and stable.
This computational triage doesn't replace the experimental pipeline, it feeds it. The molecules that score well get synthesized and tested in real assays, and results from those experiments can feed back into improving the models. It's an active and fast-moving area of pharmaceutical research, with AI-driven drug discovery companies and academic labs both actively working on it, though it's worth being cautious about specific success claims since a molecule performing well computationally is only a first step toward becoming an approved medicine.